Literature DB >> 8935341

Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach.

E Alpsoy1, E Yilmaz, E Basaran.   

Abstract

Terbinafine, an orally active antifungal agent of the allylamine class, is effective in the treatment of dermatophyte onycomycosis. Its pharmacologic and pharmacokinetic properties give strong support to the possibility that intermittent treatment courses may be equally effective in onychomycosis in general. The present randomized and controlled study was carried out to determine whether intermittent therapy with terbinafine was effective in dermatophyte toe-onychomycosis. Sixty patients with mycologically proven toenail dermatophyte onychomycosis were included in the study. Patients were equally allocated to treatment groups in a random manner. Group 1 was given 250 mg/day of terbinafine for 3 months. Group 2 was given 500 mg/day of terbinafine for 7 days during the first week of each month for 3 months. Nails were examined clinically and mycologically at monthly intervals. All patients were followed up for 48 weeks after starting the treatment. Of the patients who entered the study, 24 in Group I and 23 in Group 2 were evaluable for efficacy. At the end of the follow-up period, the cure rate (negative microscopy and culture) was 79.2% in Group 1 and 73.9% in Group 2; this difference was not significant (p: 0.79). The results indicate that intermittent therapy with terbinafine is as effective as 3-month treatment in dermatophyte toe-onychomycosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935341     DOI: 10.1111/j.1346-8138.1996.tb04009.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  7 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 2.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 3.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 6.  Onychomycosis in the elderly : drug treatment options.

Authors:  Daniel S Loo
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Common fungal infections of the feet in patients with diabetes mellitus.

Authors:  James S Tan; Warren S Joseph
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.